11/1
08:15 am
syrs
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
High
Report
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.